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AbstrACt 
Introduction Apnoeic oxygenation using nasal high-flow 
oxygen delivery systems with heated and humidified oxygen 
has recently gained popularity in the anaesthesia community. 
It has been shown to allow a prolonged apnoea time of up 
to 65 min as CO
2 increase was far slower compared with 
previously reported data from CO2 increase during apnoea. 
A ventilatory exchange due to the high nasal oxygen flow 
was proposed explaining that phenomenon. However, 
recent studies in children did not show any difference in CO
2 
clearance comparing high-flow with low-flow oxygen. To 
investigate this ventilatory exchange in adults, we plan this 
study comparing different oxygen flow rates and the increase 
of CO
2 during apnoea. We hypothesise that CO2 clearance is 
non-inferior when applying low oxygen flow rates.
Methods and analysis In this single-centre, single-blinded, 
randomised controlled trial, we randomly assign 100 patients 
planned for elective surgery to either control (oxygen 70 L/min, 
airway opened by laryngoscopy) or one of three intervention 
groups: oxygen 70, or 10, or 2 L/min, all with jaw thrust to 
secure airway patency. After anaesthesia induction and 
neuromuscular blockage, either one of the interventions 
or the control will be applied according to randomisation. 
Throughout the apnoea period, we will measure the increase 
of transcutaneous pCO
2 (tcpCO2) until any one of the following 
criteria is met: time=15 min, SpO2 <92%, tcpCO2 >10.67 kPa, 
art. pH <7.1, K+ >6.0 mmol/L. Primary outcome is the mean 
tcpCO2 increase in kPa/min.
Ethics and dissemination After Cantonal Ethic Committee 
of Bern approval (ID 2018–00293, 22.03.2018), all study 
participants will provide written informed consent. Patients 
vulnerable towards hypoxia or hypercarbia are excluded. 
Study results will be published in a peer-reviewed journal and 
presented at national and international conferences.
trial registration number This study was registered on 
www. clinicaltrials. gov (NCT03478774, Pre-results) and the 
Swiss Trial Registry KOFAM (SNCTP000002861).
IntroduCtIon
Apnoeic oxygenation was first scientifically 
described by Volhard in 1908.1 He sufficiently 
oxygenated paralysed dogs through a glass 
tube placed in the trachea without ventilation 
or respiratory movements. This only worked 
when 100% oxygen was provided, which was 
later confirmed by others.2–4 In 2015, Patel 
et al applied the same principle to high-flow 
nasal oxygenation (HFNO) but administered 
heated, humidified oxygen through nasal 
cannulas at very high flow rates up to 70 L/min 
in adults. The study group observed a lower-
than-expected rise of CO2 using this method. 
This allowed extension in apnoea time of 
patients who underwent general anaesthesia, 
even if they had difficult airways.5 A new 
term for this oxygen delivery technique was 
thus created by the study authors: THRIVE 
(transnasal humidified rapid-insufflation 
ventilatory exchange). The ventilatory effect 
is thought to happen by turbulences caused 
by the high-flow oxygen combined with the 
open mouth. These turbulences are believed 
to continue down through the trachea into 
strengths and limitations of this study
 ► Extensive measurements and rigorous study de-
sign on comparable groups allows analysis of the 
physiological response to apnoeic oxygenation and 
increasing CO
2 over time to assess a possible venti-
latory effect of nasal oxygen delivery.
 ► Randomised, direct comparison of different nasal 
oxygen flow rates to investigate their subsequent 
effect on CO2 clearance over time in order to deter-
mine the existence of a ventilatory effect.
 ► For this ‘proof of effect’ study, we include an es-
sentially healthy study population, which limits the 
transfer of results to patients with compromised 
lung function or other major health issues.
 ► Due to obvious differences in devices, anaesthetists 
cannot be blinded but it is unlikely that this will influ-
ence our primary outcome (CO2 increase).
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the alveoli, which ultimately leads to a washout of CO2. 
Thereafter, several studies described prolonged apnoea 
time without desaturation up to 65 min during contin-
uous laryngoscopy or bronchoscopy,5–7 or for laryngeal or 
tracheal surgery, where a tracheal tube would block the 
surgical field.8 
However, the physiological effects of HFNO remain 
insufficiently understood. Especially the ventilatory effect 
has not yet been proven with sufficient data. Rising CO2 
levels are the time limitation for HFNO, as they result 
in effects such as marked acidosis, increased blood pres-
sure, increased heart rate and increased cerebral blood 
flow.9–11 During the last century, PaCO2 increase in 
apnoeic patients has been repeatedly studied. According 
to that literature, PaCO2 increases rapidly during the 
first minute of apnoea (1.6–1.73 kPa), whereas after-
wards, a linear increase of about 0.4–0.67 kPa/min sets 
in.4 11–13 This physiological CO2 increase is faster than 
the one described using HFNO, which is only about 
0.15–0.24 kPa/min.
Recently, two studies showed that apnoeic oxygenation 
using low flow rates in children is equal to HFNO14 15 
without difference regarding CO2 increase. Given this 
new evidence, it seems possible that the nasal oxygen flow 
rate has little to no impact on CO2 clearance in adults as 
well.
Therefore, we will compare different nasal flow rates 
of 100% oxygen (70, 10 and 2 L/min) with HFNO (70 L/
min). Furthermore, we will apply continuous laryngos-
copy to HFNO and compare it to normal jaw thrust in the 
intervention groups in order to determine how mouth 
opening influences CO2 clearance.
We hypothesise that any of our intervention groups 
(70, 10 and 2 L/min, all with jaw thrust) is non-inferior 
to the control group (HFNO with oxygen 70 L/min using 
continuous laryngoscopy) regarding mean transcuta-
neous CO2 increase in kPa/min.
MEthods And AnAlysIs
This study is registered on www. clinicaltrials. gov 
(NCT03478774) as well as on the Swiss Trial Registry 
KOFAM (SNCTP000002861).
Aims
We want to better understand possible ventilatory effects 
during apnoeic oxygenation using nasal cannulas at 
different flow rates and demonstrate the physiological 
effects of increased CO2 levels on human physiology 
during general anaesthesia.
design
This is a single-centre, single-blinded, prospective, non-in-
feriority randomised controlled trial at the Bern Univer-
sity Hospital, Bern, Switzerland. After the study participant 
has enrolled in the study by signing the informed consent, 
he or she will be randomised using a computer-generated 
sequence. Once general anaesthesia is induced and mask 
ventilation is possible, the sealed envelope will be opened 
and oxygen flow will be provided according to randomi-
sation. Therefore, the participant is blinded towards his 
or her group allocation, but anaesthesiologists cannot be 
blinded, because devices clearly differ from each other. 
Once randomised, the participant will stay in the allo-
cated group for analysis, even if another intervention is 
applied (intention-to-treat).
study population
Possible participants will be screened for eligibility 
checking the surgical schedule and we invite them to 
participate during our pre-anaesthesia interview. To 
allow patients sufficient time to consider participation, 
we contact eligible study participants the day before 
surgery. We will include adults (>18 years of age), who 
will undergo elective surgery requiring general anaes-
thesia, with an American Society of Anesthesiologists 
(ASA) physical health status I-III, SpO2 ≥96% breathing 
room air, and who provide written informed consent in 
German as this is the common language spoken in Bern, 
Switzerland.
Because we intend to study the impact of apnoeic 
oxygenation on the accumulation of CO2, we will exclude 
all patients who—through their underlying condi-
tion—could bias or influence the normal physiological 
response. Also, for patient safety reasons, we will exclude 
patients who might be harmed due to study-related effects 
or measurements. Specifically, we exclude:
 ► Patients with risk factors for difficult airway (indica-
tion for flexible optic intubation, high risk of regurgi-
tation or expected difficult mask ventilation).
 ► Vulnerability towards hypoxaemia (known coronary 
heart disease, peripheral occlusive arterial disease, 
known stenosis of the carotid or vertebral arteries, 
anaemia or pregnancy).
 ► Vulnerability towards hypercarbia (pulmonary arte-
rial hypertension, increased intracranial pressure, 
intracranial surgery or hyperkalaemia).
 ► Obstructive sleep apnoea, nasal obstruction, body-
mass index <16 kg/m2 or >35 kg/m2 or known, 
suspected cervical spine instability, neuromuscular 
disorder, absent power of judgement, limited knowl-
edge of German language, allergies towards any of the 
used agents.
In order to further reduce potential bias, we will stratify 
randomisation according to body-mass index (BMI) 
into three groups (16–25, 25–30 and 30–35 kg/m2) and 
according to smoker status into four groups (non-smokers, 
non-daily smokers, daily smokers <40 years of age and 
daily smokers >40 years of age). According to the BMI, 
smoking status and age group, the patient fits into one 
of the possible 12 strata. Within each strata, the groups 
are being randomised for the different flow rates. Partic-
ipants will be randomised in a 1:1:1:1 ratio (25 patients 
per group) using a computer-generated sequence which 
will be executed by a study nurse.
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sample size
Patel et al showed an increase of only 0.15 kPa/min with a 
flow rate of 70 L O2/min and maximal mouth opening.
5 
However, end-tidal CO2 was measured, not transcuta-
neous tcpCO2. Gustafsson et al measured both, tcpCO2 
as well as arterial pCO2, and found a CO2 increase of 
0.24 kPa/min, with a SD of 0.05 kPa, which was almost 
twice as high as the tcpCO2 value.
6 Using a non-inferiority 
design, a difference of means of 0.04 kPa/min, a SD of 
0.05 kPa/min, an alpha of 0.025 (one-sided) with a power 
of 80%, revealed a necessary sample size of 22 patients 
per group. We will include 25 patients in each group 
(100 patients in total) to account for possible dropouts. A 
difference of means of 0.04 kPa/min CO2 increase would 
still only result in an absolute difference of 1.2 kPa CO2 
after 30 min of apnoea time. We defined this as measur-
able, but still clinically acceptable and therefore non-infe-
rior because the normal range of standard arterial pCO2 
is 1.3 kPa (4.7–6.0 kPa).16
Procedure
Once written informed consent is obtained and preg-
nancy is excluded in female patients by a pregnancy 
test, we will extract demographic data from the hospital 
information system. This includes data collected through 
routine patients’ workflow: age, sex, weight, height, BMI, 
airway risk factors (Mallampati score, mouth opening, 
thyromental distance, reduced neck movement, retrog-
nathia, and dental status) underlying diseases, smoking 
habits, ASA physical health status and indication for 
surgery.
On the day of surgery, we will place an arterial cannula 
into the radial artery under local anaesthesia and draw 
arterial blood gases from the awake study participant 
breathing room air as a baseline measurement. We will 
instal (1) standard anaesthesia monitoring: EKG, pulse 
oximetry, invasive blood pressure, end-tidal O2, end-tidal 
CO2, train of four (TOF), Narcotrend EEG (Narcotrend, 
Hannover, Germany), and (2) study-related monitoring: 
cardiac output (LiDCO, LiDCO Ltd, London, UK), 
thoracic electric impedance tomography (EIT; using 
PulmoVista 500, by Dräger, Lübeck, Germany), bilateral 
near-infrared spectroscopy (NIRS; using Niro-200NX, 
Hamamatsu, Tokyo, Japan) and transcutaneous pCO2and 
pO2 (tcpO2) measurement (both via TCM5, Radiometer, 
Thalwil, Switzerland). After that, we will start bag-mask 
preoxygenation until end-tidal O2 has reached 90%. 
Patients will receive a fentanyl bolus of 2 µg/kg, and induc-
tion of anaesthesia will begin using a target-controlled 
infusion (TCI, Schnider model using syramed µSP6000, 
Arcomed AG, Regensdorf, Switzerland) for propofol with 
a target concentration of 3.0 µg/mL and TCI for remifen-
tanil (Minto model using syramed µSP6000, Arcomed 
AG, Regensdorf, Switzerland) with a target concentration 
of 2.0 ng/mL. We will administer rocuronium 0.9 mg/
kg to achieve neuromuscular blockage. After induction, 
general anaesthesia will be confirmed by absent end-tidal 
CO2 readings, unconsciousness and Narcotrend-values in 
the target range of 40–60 under bag-mask ventilation.
Once mask ventilation with a tidal volume of 6 mL/kg 
and a respiratory rate of 12/min is successful, the previ-
ously sealed envelope containing the randomisation 
will be opened and the intervention will be prepared 
according to group allocation.
For safety reasons, the experiment will be discontinued 
if mask ventilation is impossible even after full neuro-
muscular blockage and placement of an oropharyngeal 
tube. The anaesthetist in charge would then intubate the 
trachea and no study-related measurements would take 
place.
For all patients who show a cardiovascular reaction 
(an increase of heart rate and blood pressure) to the 
study procedure (laryngoscopy or jaw thrust), we will 
titrate remifentanil to effect. Once a steady state has set in, 
we will no longer interfere with remifentanil. Whenever 
Narcotrend values rise above our target range, propofol 
will be increased. We will not correct dropping Narcotrend 
values as this is likely to be caused by increasing CO2 and 
therefore an effect we want to measure.
When complete neuromuscular blockage has been 
confirmed by TOF=0, we will stop mask ventilation and 
start the apnoea time. Arterial blood gas will be drawn 
and analysed at the start of apnoea.
If assigned to the control group, the study participant will 
receive high-flow humidified oxygen at 70 L/min via Opti-
flow (Fisher&Paykel, Auckland, NewZealand) throughout 
the apnoea period while the glottis will be visualised by 
video laryngoscopy (MacGrath MAC, Medtronic, Dublin, 
Ireland), thus assuring airway patency. If assigned to one 
of the intervention groups, one of the senior anaesthesia 
researchers will apply jaw thrust and one of the following 
flow rates: (1) high-flow humidified oxygen at 70 L/
min via Optiflow; (2) medium-flow humidified oxygen 
at 10 L/min (Carbamed digiflow, Switzerland; Aquapak 
Hudson RCI, Teleflex, Wayne, Pennsylvania, USA; O2Star 
nasal cannula curved, Dräger, Lübeck, Germany); or (3) 
low-flow humidified oxygen at 2 L/min (Carbamed digi-
flow, Switzerland; Aquapak Hudson RCI, Teleflex, Wayne, 
Pennsylvania, USA; O2Star nasal cannula curved, Dräger, 
Lübeck, Germany) (figure 1).
During jaw thrust, upper airway patency will be visually 
confirmed by a nasopharyngeal fiberscope (EF-N slim, 
Acutronic, Hirzel, Switzerland).17 Only if the airway is 
obstructed, we will insert an oropharyngeal airway tube 
(Guedel airway, Intersurgical, Workingham, Berkshire, 
UK). We will not assess the degree of opening, as this 
would not have any direct consequences for the study.
During apnoea time, we will continuously measure 
invasive arterial blood pressure, pulse oximetry and 
EKG as part of standard monitoring. Furthermore, we 
will continuously measure tcpCO2, tcpO2 by applying a 
probe to the patient’s chest, two fingers below the clav-
icle; depth of anaesthesia (Narcotrend); bilateral brain 
oxygenation (NIRS); cardiac output by pulse contour 
analysis; and ventilation distribution changes by thoracic 
 o
n
 D
ecem
ber 2, 2019 at E-Library Insel. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025442 on 11 July 2019. Downloaded from 
4 Theiler L, et al. BMJ Open 2019;9:e025442. doi:10.1136/bmjopen-2018-025442
Open access 
electrical impedance tomography. For this, resulting 
potential differences are measured, and impedance 
distribution sampled at 30 Hz will be calculated by an 
automated linearised Newton-Raphson reconstruction 
algorithm.18 Relative change in end-expiratory lung 
impedance (EELI) and measures of ventilation inhomo-
geneity such as the global inhomogeneity index will be 
calculated as described previously, using customised soft-
ware (Matlab R2013a, The MathWorks, Nattick, Massa-
chusetts, USA).19 20
Furthermore, we will take arterial blood samples at 
the onset of apnoea, 1 min after apnoea, and thereafter 
every 2 min to perform blood gas analysis (total of max. 
10 measurements). These blood samples will be analysed 
for PaO2, SaO2, PaCO2, pH, bicarbonate and potassium.
During the induction of anaesthesia, potential hypo-
tension due to the anaesthetic drugs will be counteracted 
with a continuous infusion of norepinephrine. Thereafter, 
a steady state will set in and any change in blood pres-
sure is due to the vasoactive effect of CO2. As we want 
to measure these effects, we will no longer interfere with 
blood pressure, except for persisting hypotension.
The experiment will end when any of the following 
criteria is met: SpO2 <92%, ptcCO2 >10.67 kPa, pH <7.1, 
K+ >6.0 mmol/L, t=15 min. Thereafter the trachea will 
be intubated according to the decision of the attending 
anaesthetists. With that, the presurgical part of the study 
will end.
Study participants will either be visited on the ward or 
contacted by phone on the first postoperative day in the 
morning to ask about the quality of recovery.21 22 This 
includes the ability to breathe easily, feeling rested, being 
able to enjoy food, getting support from hospital doctors 
and nurses as well as any pain, nausea and vomiting, 
feeling worried or anxious, or feeling sad or depressed. 
Furthermore, we ask specifically for pain localised in the 
Figure 1 Study flowchart. 
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patient’s throat, mandibular joint, or head; nasal dryness; 
lip injuries; dental damages; other injuries; or any other 
discomfort or complication. For assessing the severity of 
complications, we will use a (modified) visual analogue 
scale (VAS), where 0 is no pain (or discomfort) and 10 
is maximum pain (or discomfort). We will also assess all 
injuries obtained during airway management and the 
study period. After this interview, no further data will be 
acquired and the study ends.
objectives
Primary outcome
Our primary outcome is to measure the increase of mean 
transcutaneous CO2 over time in kPa/min and to deter-
mine the influence of nasal oxygen flow rate (70, 10 and 
2 L/min) and the presence of an open mouth (jaw thrust 
vs continuous laryngoscopy).
Secondary outcomes
Secondary outcomes are: lowest O2 saturation; changes 
in EELI, which will help quantify the degree of atelectasis 
after intubation, and influence of increasing CO2 on: 
cardiac output and systemic blood pressure, invasive arte-
rial blood pressure, pulse oximetry and EKG as part of 
standard monitoring, tcpO2, depth of anaesthesia, bilat-
eral brain oxygenation (NIRS), arterial blood gas analysis 
(PaO2, SaO2, PaCO2, pH, bicarbonate and potassium). 
Furthermore: postoperative pain, nausea and vomiting, 
feeling worried or anxious, or feeling sad or depressed, 
injuries or any other discomfort or complication.
statistical plan
Distribution of data will be checked for normality using 
qq-plots and the Shapiro-Wilks analysis using Stata 
(StataCorp LLC, College Station, Texas, USA). For our 
primary outcome parameter, the rise of ptcCO2, we will use 
a linear mixed model using groups and minutes. Normal 
distributed data will be presented as means and SD, other-
wise median and IQR will be used. Proportions will be 
presented as numbers and percentage. Analytical statistics 
uses Mann-Whitney U test and Student’s t-test, according 
distribution, or ANOVA and Kruskal-Wallis for multiple 
group comparisons. Each of the groups will a priori be 
compared with the control group independently, there-
fore no correction for multiple comparisons will have to 
be used. Other multiple comparisons and any subgroup 
analyses will be performed using appropriate correction 
factors. Proportions will be compared by χ2 test or Fisher 
exact test. As sensitivity analyses, we will do regression 
analyses, using mixed effects linear regressions. All statis-
tical analyses will be performed on an intention-to-treat 
basis. We will also include a per-protocol analysis in order 
to minimise bias for the standard treatment group. If 
the results of such an analysis are consistent with those 
from the intention-to-treat approach and if both lie below 
the non-inferiority threshold, the inference regarding 
non-inferiority is strengthened. A p<0.05 will be consid-
ered statistically significant.
Patient involvement
No patients or patient representatives were involved in 
the design of this trial.
Ethics and dissemination
This study will be conducted in accordance with the 
International Conference on Harmonisation  Note for 
Guidance on Good Clinical Practise (ICH GCP) and 
local regulations with the approval of the Cantonal Ethics 
Committee Bern, following the Swiss law for human 
research.23 The ethics committee already approved our 
study (ID 2018–00293), including the safety endpoints. 
A drop in O2 saturation <92% allows for timely securing 
the airway without risk of hypoxic damages of the study 
participants. Furthermore, prior publications suggest it 
to be very likely that all groups maintain stable O2 satura-
tion throughout the maximum apnoea time of 15 min.24 25 
Rising CO2 levels could lead to acidosis; therefore, patients 
vulnerable to hypercarbia are excluded preliminarily (see 
the Study population section). As routinely stated in the 
protocol for the ethics committee, the study can be termi-
nated prematurely if new evidence suggesting severe 
disadvantage or increased morbidity will arise during the 
study period.
All study data will be directly recorded in the case 
report form (CRF), which should also be considered 
being source data. These data will be transferred into the 
departmental research documentation system—LabKey 
(LabKey Software, Seattle, Washington, USA, V.14.3). 
All study data will be archived for a minimum of 10 years 
after study termination or premature termination of the 
clinical trial.
Data will be transferred into a secure, web-based data 
integration platform and controlled independently by 
two members of the study team. Additionally, data are 
double-checked by comparing the screening records 
with the digital anaesthesia documenting system of the 
hospital.
A study nurse otherwise not involved in the study will 
be in charge of data monitoring and auditing after every 
20 patients.
Important modifications to the protocol will have to be 
reported to the ethics committee.
Both the principal investigator and sponsor investigator 
will have access to the final trial dataset. Other researchers 
may be granted access to the dataset to answer scientific 
questions.
Results will be presented at national and international 
scientific meetings and will be published in a peer-re-
viewed medical journal.
Informed consent
In order to be eligible for the study, all patients have to 
sign an ethics committee approved informed consent 
form. All potential risks and benefits will be thoroughly 
explained by study personnel and the patient will be given 
enough time to consider his or her study participation.
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dIsCussIon
Humidified HFNO is a widely used therapy in inten-
sive care for both adults and paediatric spontaneously 
breathing patients. The new use in patients under general 
anaesthesia has revitalised the old concept of apnoeic 
oxygenation. Its use in anaesthesiology spreads from 
oxygenating an awake patient to pre-oxygenation, as well 
as to apnoeic oxygenation during rapid-sequence intuba-
tion (RSI), or during microlaryngoscopy and bronchos-
copy. More and more applications for humidified HFNO 
or THRIVE are emerging and they show great potential.
However, there is only limited evidence explaining 
physiological changes during HFNO, especially the 
proposed mechanism of CO2 elimination by a ventilatory 
effect in anaesthetised patients. It remains unknown how 
different flow rates affect CO2 clearance and if a minimal 
flow rate (of 2 L/min) is able to maintain oxygenation 
over 15 min. There are a few studies suggesting lower flow 
rates could also be effective.24 25 However, no prospective 
study compared high flow with low flow so far; and it has 
not yet been determined how flow rate influences CO2 
clearance. As high CO2 levels have a multitude of effects, 
such as pulmonic arterial vasoconstriction, acidosis and 
hyperkalaemia, a better understanding of CO2 clear-
ance could lead to the definition of contraindications 
or safety measurements for humified HFNO/THRIVE, 
especially for longer apnoea periods (eg, during micro 
laryngoscopy).
It is not known whether changes of thoracic EIT in 
anaesthetised patients are similar to those in awake 
patients.26 For example, it is already known that EELI 
is increased in awake patients. This is probably due to 
a higher pharyngeal pressure observed in patients with 
HFNO who breathe spontaneously. The effect has never 
been evaluated in anaesthetised patients.27 28
Also, haemodynamic changes during apnoeic oxygen-
ation and under increasing PaCO2 have not yet been 
investigated rigorously. We only found studies describing 
increased PaCO2 and its influence on cardiac output and 
brain perfusion in awake patients and healthy volun-
teers.9 10 29 It is very likely that anaesthetised patients have 
a different reaction due to the vasodilatory effect of most 
anaesthetic drugs, which could very easily overweigh the 
vasoconstrictive effects of increased CO2 levels.
Overall, knowledge of the underlying physiological 
mechanisms during HFNO in anaesthetised patients 
is still very limited. This study investigates under rigor-
ously controlled circumstances the concept of humid-
ified HFNO on prolonged apnoea time, presumably 
without desaturation. With our findings, we hope to 
improve airway management safety as this study enables 
the medical community to better understand the physi-
ology behind apnoeic oxygenation and the influence of 
different nasal flow rates on CO2 clearance. Our study’s 
extensive setup also allows us to measure the effects of 
increased CO2 on cerebral perfusion and cardiac output.
If low-flow oxygen administration with standard 
nasal cannula is non-inferior compared with high-flow 
humidified HFNO, it could have a direct clinical impact. 
Oxygen and standard nasal cannula are ubiquitously 
available and it will be hard to argue against apnoeic 
oxygenation during routine intubation. Especially for RSI 
and other emergency airway procedures, apnoeic oxygen-
ation may be—and perhaps should be—performed using 
a standard nasal cannula at a low flow rate.30 For patients 
at risk of desaturation, this has the potential to reduce 
complication of hypoxia and therefore will improve 
patient safety with little additional resources.
Due to the design of this trial, we will not be able to 
determine the influence of pathophysiological alterations 
of patients’ underlying diseases, as we exclude severely ill 
patients from this study for safety reasons. Furthermore, 
although we include 100 patients in this trial, we may 
still end up with an uneven distribution of risk factors. 
To minimise this bias, we stratify according to BMI and 
smoking status, as we assume these factors to be the most 
influential on our primary outcome.
Provided all groups have a similar CO2 clearance, the 
inclusion of 100 patients will provide a solid foundation to 
detect even smaller haemodynamic, thoracic EIT or EEG 
changes. Nevertheless, all results are to be considered 
for anaesthetised patients using propofol and remifent-
anil. We do not know how other anaesthetic drugs would 
potentially interfere with patients’ physiology.
All this leads us to the conclusion that this study will 
be able to provide highly interesting results and urgently 
needed evidence on physiological changes during HFNO 
and CO2 increase in adult patients during apnoeic 
oxygenation. We will find an answer to our question, if 
the application of nasal oxygen at 70, 10 or 2 L/min using 
a jaw thrust is non-inferior compared with nasal oxygen 
at 70 L/min using continuous laryngoscopy in regard to 
CO2 clearance in anaesthetised patients.
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